Alumis and Kaken Pharmaceutical Announce Collaboration and - GlobeNewswire
  KalVista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan - Business Wire
  KalVista, awaiting FDA call on HAE drug, sells Japanese rights to Kaken in $22M deal - Fierce Biotech
  Whitehawk Therapeutics Completes Strategic Transformation with Successful Closing of Sale of Aadi Subsidiary to Kaken Pharmaceuticals - PR Newswire
  KalVista licences HAE therapy commercialisation rights to Kaken - Pharmaceutical Technology
  $180M Deal: Alumis Partners With Japanese Pharma Giant for Revolutionary Skin Disease Drug - Stock Titan
  Alumis and Kaken Pharma ink deal for ESK-001 in dermatology in Japan - The Pharma Letter
  J'J expands atopic dermatitis pipeline with Kaken Pharmaceutical licensing deal - PMLiVE